The Role of Hypoxia in Cancer Progression, Angiogenesis, Metastasis and Resistance to Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 1263

Special Issue Editor

Department of Oncology, MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
Interests: hypoxia; invasion; metastasis; ferroptosis; oxidative stresses; metabolism; hyperthermia

Special Issue Information

Dear Colleagues,

Hypoxia, which results from an imbalance between oxygen supply and consumption, is one of the key features of the tumour microenvironment. Its complicating role in tumour progression through the regulation of angiogenesis, metastasis, immune evasion, and resistance to therapy continues to draw our attention towards targeting hypoxia and its relevant factors, in order to enhance cancer patient outcome.

This Special Issue focuses on presenting our knowledge about tumour hypoxia, covering our past, current, and future understanding. It will present an overview of how our attempts to assess and target hypoxia have evolved over time and introduce new perspectives from leading experts in the field. We hope that this issue can provide a platform for further research and development in this field.

Dr. Ejung Moon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypoxia
  • cancer
  • progression
  • angiogenesis
  • metastasis
  • immune evasion
  • resistance to therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1704 KiB  
Review
Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells
by Peter Wai Tik Lee, Lina Rochelle Koseki, Takao Haitani, Hiroshi Harada and Minoru Kobayashi
Cancers 2024, 16(9), 1729; https://doi.org/10.3390/cancers16091729 - 29 Apr 2024
Viewed by 869
Abstract
In hypoxic regions of malignant solid tumors, cancer cells acquire resistance to conventional therapies, such as chemotherapy and radiotherapy, causing poor prognosis in patients with cancer. It is widely recognized that some of the key genes behind this are hypoxia-inducible transcription factors, e.g., [...] Read more.
In hypoxic regions of malignant solid tumors, cancer cells acquire resistance to conventional therapies, such as chemotherapy and radiotherapy, causing poor prognosis in patients with cancer. It is widely recognized that some of the key genes behind this are hypoxia-inducible transcription factors, e.g., hypoxia-inducible factor 1 (HIF-1). Since HIF-1 activity is suppressed by two representative 2-oxoglutarate-dependent dioxygenases (2-OGDDs), PHDs (prolyl-4-hydroxylases), and FIH-1 (factor inhibiting hypoxia-inducible factor 1), the inactivation of 2-OGDD has been associated with cancer therapy resistance by the activation of HIF-1. Recent studies have also revealed the importance of hypoxia-responsive mechanisms independent of HIF-1 and its isoforms (collectively, HIFs). In this article, we collate the accumulated knowledge of HIF-1-dependent and independent mechanisms responsible for resistance of hypoxic cancer cells to anticancer drugs and briefly discuss the interplay between hypoxia responses, like EMT and UPR, and chemoresistance. In addition, we introduce a novel HIF-independent mechanism, which is epigenetically mediated by an acetylated histone reader protein, ATAD2, which we recently clarified. Full article
Show Figures

Figure 1

Back to TopTop